Skip to main content

Table 1 Patient and disease characteristics pre-ablation

From: Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging

Characteristic

Value

PSA (ng/ml), median (IQR)

8.7 (6.7, 11.76)

TRUS Prostate Volume (cc), median (IQR)

35 (24.3, 47.7)

No. prior biopsy sessions, median (IQR)

3 (2,3)

MRI lesion volume (mL), median (IQR):

 

 Overall

2 (0.86, 3.1)

 PGG 1

2 (0.74, 2.94)

 PGG 2

2.04 (0.98, 4.5)

Biopsy type:

 Fusion, No. (%)

12 (71)

 TTMB, No. (%)

5 (29)

No. cores, mean (range)

24.8 (1, 68)

No. positive cores b (%):

 1

11 (64.7)

 2

4 (23.5)

 4

2 (11.8)

PGG, No. (%)

 1

12 (71)

 2

5 (29)

  1. PGG prognostic grade group, TTMB transperineal template-guided prostate mapping biopsy
  2. Includes most recent biopsy performed at Duke
  3. Most recent biopsy performed at Duke prior to cryoablation